Clinical Trial · NCT06389097

SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization

Overview

The investigators will study SPECT imaging of radiopharmaceutical therapies given as standard of care or as part of other compatible research protocols. The goal is to validate the quantitative SPECT image reconstruction methods developed in this proposal, and to investigate the relation between dosimetry calculated from SPECT images and the outcomes. Patients will be recruited for SPECT/CT imaging during treatment. This is an observational study no additional new drugs or activities will be administrated. The investigators will perform SPECT imaging on a total of 80 patients (\~20 each from year 2 to year 5). Each participant will be imaged 3 times after the first and last cycles of planned radiopharmaceutical therapy.

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Contacts

Ryan Manuel (CONTACT)

rmanuel5@jhmi.edu

410-955-4261

Ana Kiess, MD, PhD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT06389097

Drug / Compound

Radium-223

Isotope(s):

Target(s):

Bone Metabolism

DOTATATE

Isotope(s):

Target(s):

SSTR2

Ligand Class: Peptides

Chelator: DOTA

PSMA-617

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Chelator: DOTA

Eligibility

Inclusion

Cohort B: Patients with advanced cancer undergoing treatment with 177Lu-DOTATATE or 177Lu-PSMA-617 \*\*Eligible patients may be planning to undergo these treatments as part of standard of care or as part of another research protocol
Cohort A: Patients with advanced prostate cancer planning to undergo treatment with Radium-223
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

Exclusion

Exclusion criteria not yet provided.